Juergen Kv Reichardt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/697592/publications.pdf

Version: 2024-02-01

53	1,775	304743	276875
papers	citations	22 h-index	41 g-index

56	56	56	2179
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hormones and prostate cancer: Current perspectives and future directions. Prostate, 2002, 52, 213-235.	2.3	178
2	Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Human Mutation, 1999, 13, 417-430.	2.5	145
3	COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. Human Genomics, 2020, 14, 17.	2.9	95
4	Molecular Basis of Disorders of Human Galactose Metabolism: Past, Present, and Future. Molecular Genetics and Metabolism, 2000, 71, 62-65.	1.1	90
5	Multiplex Automated Primer Extension Analysis: Simultaneous Genotyping of Several Polymorphisms. BioTechniques, 2001, 31, 1374-1380.	1.8	85
6	A Genetic Factor for Age-Related Cataract: Identification and Characterization of a Novel Galactokinase Variant, â€œOsaka,â€•in Asians. American Journal of Human Genetics, 2001, 68, 1036-1042.	6.2	80
7	The fundamental importance of human galactose metabolism: lessons from genetics and biochemistry. Trends in Genetics, 1998, 14, 98-102.	6.7	76
8	Characterization of a novel biochemical abnormality in galactosemia: Deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochemical Medicine and Metabolic Biology, 1991, 46, 93-104.	0.7	68
9	Associations between polymorphisms in the steroid 5-Î± reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancerâ˜†. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 246-253.	1.6	64
10	Genetic variation of 3Î²-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk. , 1997, 33, 9-12.		63
11	The Gutâ€“Brain Axis, Paving the Way to Brain Cancer. Trends in Cancer, 2019, 5, 200-207.	7.4	57
12	Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene. Journal of Pediatrics, 1994, 125, 225-227.	1.8	56
13	Does the racial-ethnic variation in prostate cancer risk have a hormonal basis?. Cancer, 1995, 75, 1778-1782.	4.1	53
14	Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate, 2002, 53, 65-68.	2.3	51
15	Human UDP-Galactose 4â€² Epimerase (GALE) Gene and Identification of Five Missense Mutations in Patients with Epimerase-Deficiency Galactosemia. Molecular Genetics and Metabolism, 1998, 63, 26-30.	1.1	47
16	Genetic susceptibility to cancer from exogenous and endogenous exposures. Journal of Cellular Biochemistry, 1996, 63, 15-22.	2.6	46
17	Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Journal of Urology, 2010, 184, 2297-2302.	0.4	38
18	Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Review of Anticancer Therapy, 2012, 12, 811-837.	2.4	37

#	Article	IF	Citations
19	No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Human Molecular Genetics, 2008, 17, 2456-2461.	2.9	32
20	Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Molecular Brain Research, 2005, 136, 99-103.	2.3	31
21	SOMATIC MUTATIONS AT THE SRD5A2 LOCUS ENCODING PROSTATIC STEROID 5 alpha-REDUCTASE DURING PROSTATE CANCER PROGRESSION. Journal of Urology, 1999, 161, 1355-1358.	0.4	29
22	Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes and Control, 2002, 13, 113-120.	1.8	28
23	Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncology, 2008, 4, 525-534.	2.4	27
24	Androgens and the molecular epidemiology of prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 261-270.	2.3	23
25	Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 2011, 32, 1500-1506.	2.8	23
26	Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis. BMC Genomics, 2016, 17, 56.	2.8	21
27	In vitro readâ€through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria. Journal of Inherited Metabolic Disease, 2013, 36, 955-959.	3.6	20
28	Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience. Cancer Prevention Research, 2010, 3, 1523-1533.	1.5	19
29	Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics, 2001, 2, 65-72.	1.3	18
30	Molecular Epidemiology of Androgen-Metabolic Loci in Prostate Cancer: Predisposition and Progression. Journal of Urology, 2004, 171, S25-8; discussion S28-9.	0.4	17
31	A reliable PCR amplification method for microdissected tumor cells obtained from paraffin-embedded tissue. Genetic Analysis, Techniques and Applications, 1999, 15, 229-233.	1.5	16
32	Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. Human Mutation, 2009, 30, 39-48.	2.5	16
33	Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncology, 2010, 6, 1897-1913.	2.4	15
34	A renaissance of â€œbiochemical geneticsâ€? SNPs, haplotypes, function, and complex diseases. Molecular Genetics and Metabolism, 2004, 83, 47-50.	1.1	14
35	Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics, 2007, 8, 645-661.	1.3	14
36	Molecular analysis of 11 galactosemia patients. Nucleic Acids Research, 1991, 19, 7049-7052.	14.5	10

#	Article	IF	Citations
37	Three new mutations (P183T, V150L, 528insG) and eleven sequence polymorphisms in Italian patients with galactose-1-phosphate uridyltransferase (GALT) deficiency. , 1996, 8, 369-372.		8
38	Identification of mutations in the galactose-1-phosphate uridyltransferase (GALT) gene in 16 Turkish patients with galactosemia, including a novel mutation of F294Y. Human Mutation, 1999, 13, 339-339.	2.5	8
39	Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease. Urology, 2015, 85, 616-620.	1.0	8
40	Single Nucleotide Differences (SNDs) Continue to Contaminate the dbSNP Database With Consequences for Human Genomics and Health. Human Mutation, 2015, 36, 196-199.	2.5	8
41	Human genetics and genomics meetings going virtual: practical lessons learned from two international meetings in early 2020. Human Genomics, 2020, 14, 27.	2.9	8
42	Pharmacogenetics of human androgens and prostate cancer â€“ an update. Pharmacogenomics, 2004, 5, 283-294.	1.3	7
43	Androgen Receptor CAG Repeat Length andÂTMPRSS2:ETS Prostate Cancer Risk:ÂResults From the Prostate Cancer Prevention Trial. Urology, 2014, 84, 127-131.	1.0	6
44	Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Oncotarget, 2016, 7, 74860-74871.	1.8	5
45	Unexpected biochemical and pharmacogenetic consequences of SNPs and haplotypes: a cautionary tale for human molecular genetics and epidemiology. Genomics, 2006, 88, 673-674.	2.9	4
46	Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease. Human Genomics, 2020, 14, 22.	2.9	4
47	Schwannomas exhibit distinct size-dependent gene-expression patterns. Future Oncology, 2015, 11, 1751-1758.	2.4	3
48	Prostatic Steroid 5Î±-Reductase, an Androgen Metabolic Gene. Mayo Clinic Proceedings, 2000, 75, S36-S39.	3.0	1
49	Realizing the full potential of the sequenced human genome. Trends in Genetics, 2008, 24, 219-220.	6.7	1
50	Reflections of a Biomedical Scientist on Four Continents in Interdisciplinary Research. Trends in Genetics, 2018, 34, 401-403.	6.7	1
51	Genomics in breast and prostate cancer: assessment of the current state and future perspectives. Future Oncology, 2006, 2, 357-362.	2.4	0
52	Ecuadorâ€™s research dream crushed by politics. Nature, 2019, 574, 333-333.	27.8	0
53	Androgen-Metabolic Genes in Prostate Cancer Predisposition and Progression. , 2009, , 141-154.		0